Radiation recall phenomenon secondary to capecitabine

Possible role of thymidine phosphorylase

Muhammad Wasif Saif, Glenda Black, Martin Johnson, Suzanne Russo, Robert B Diasio

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The first reported case of radiation (XRT) recall related to capecitabine described dermatitis in a previously radiated field in a breast cancer patient (Ortman; JCO). We previously reported the first case of recall syndrome manifesting as diffuse gastritis and duodenitis related to capecitabine with prior XRT with 5-FU in a pancreatic cancer patient (Saif; JARCET). We report here another pancreatic cancer patient with a radiation recall receiving capecitabine following capecitabine-XRT. Patients and methods: From April 2004 to June 2005, 20 patients with locally advanced pancreatic adenocarcinoma were treated with capecitabine 1,600 mg/m 2 daily with concomitant radiation (5040cGy) Monday-Friday (weekends off) for a total of 6 weeks, followed by capecitabine 2,000 mg/m 2 daily for 14 days every 3 weeks. One male patient with tumor in the neck and body of pancreas and not infiltrating the duodenum dropped hemoglobin to 7.3 g/dl at the end of the ninth week, and melena on rectal examination. Specimen of primary pancreatic ductal adenocarcinoma was obtained via EUS-guided biopsy before starting XRT on day 1 and utilized for RNA extraction. TP mRNA level was determined by real-time quantitative PCR (RT-Q-PCR). Results: Upper endoscopy revealed gastritis consistent with radiation toxicity. Colonoscopy was negative. Transfusion of three units of packed red blood cells (PRBCs) was given. The dose of capecitabine was reduced by 25%. His anemia continued to progress, a CT scan revealed 39% decrease in the tumor size (PR). Analysis of tumor specimen prior to the start of capecitabine-XRT showed TP expression of 183.16 (high). In addition to TP, DPD was 7.40, and TNF-alpha 4,114.56. Conclusion: We believe this case to be the second case of radiation recall presenting as diffuse gastritis in a patient receiving capecitabine after previous treatment with XRT. Further studies, including the role of TP are warranted into the pathogenesis of this unique phenomenon.

Original languageEnglish (US)
Pages (from-to)771-775
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume58
Issue number6
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Thymidine Phosphorylase
Radiation
Gastritis
Tumors
Pancreatic Neoplasms
Adenocarcinoma
Dermatitis
Duodenitis
Melena
Capecitabine
Neoplasms
Endoscopy
Computerized tomography
Biopsy
Colonoscopy
Duodenum
Fluorouracil
Toxicity
Anemia
Real-Time Polymerase Chain Reaction

Keywords

  • Capecitabine
  • Dihydropyrimidine dehydrogenase (DPD)
  • Fluorouracil (5-FU)
  • Pancreatic cancer
  • Radiation recall phenomenon
  • Thymidine phosphorylase (TP)
  • Xeloda

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Radiation recall phenomenon secondary to capecitabine : Possible role of thymidine phosphorylase. / Saif, Muhammad Wasif; Black, Glenda; Johnson, Martin; Russo, Suzanne; Diasio, Robert B.

In: Cancer Chemotherapy and Pharmacology, Vol. 58, No. 6, 12.2006, p. 771-775.

Research output: Contribution to journalArticle

Saif, Muhammad Wasif ; Black, Glenda ; Johnson, Martin ; Russo, Suzanne ; Diasio, Robert B. / Radiation recall phenomenon secondary to capecitabine : Possible role of thymidine phosphorylase. In: Cancer Chemotherapy and Pharmacology. 2006 ; Vol. 58, No. 6. pp. 771-775.
@article{a2746c9161ae484ea6be722716b53119,
title = "Radiation recall phenomenon secondary to capecitabine: Possible role of thymidine phosphorylase",
abstract = "Background: The first reported case of radiation (XRT) recall related to capecitabine described dermatitis in a previously radiated field in a breast cancer patient (Ortman; JCO). We previously reported the first case of recall syndrome manifesting as diffuse gastritis and duodenitis related to capecitabine with prior XRT with 5-FU in a pancreatic cancer patient (Saif; JARCET). We report here another pancreatic cancer patient with a radiation recall receiving capecitabine following capecitabine-XRT. Patients and methods: From April 2004 to June 2005, 20 patients with locally advanced pancreatic adenocarcinoma were treated with capecitabine 1,600 mg/m 2 daily with concomitant radiation (5040cGy) Monday-Friday (weekends off) for a total of 6 weeks, followed by capecitabine 2,000 mg/m 2 daily for 14 days every 3 weeks. One male patient with tumor in the neck and body of pancreas and not infiltrating the duodenum dropped hemoglobin to 7.3 g/dl at the end of the ninth week, and melena on rectal examination. Specimen of primary pancreatic ductal adenocarcinoma was obtained via EUS-guided biopsy before starting XRT on day 1 and utilized for RNA extraction. TP mRNA level was determined by real-time quantitative PCR (RT-Q-PCR). Results: Upper endoscopy revealed gastritis consistent with radiation toxicity. Colonoscopy was negative. Transfusion of three units of packed red blood cells (PRBCs) was given. The dose of capecitabine was reduced by 25{\%}. His anemia continued to progress, a CT scan revealed 39{\%} decrease in the tumor size (PR). Analysis of tumor specimen prior to the start of capecitabine-XRT showed TP expression of 183.16 (high). In addition to TP, DPD was 7.40, and TNF-alpha 4,114.56. Conclusion: We believe this case to be the second case of radiation recall presenting as diffuse gastritis in a patient receiving capecitabine after previous treatment with XRT. Further studies, including the role of TP are warranted into the pathogenesis of this unique phenomenon.",
keywords = "Capecitabine, Dihydropyrimidine dehydrogenase (DPD), Fluorouracil (5-FU), Pancreatic cancer, Radiation recall phenomenon, Thymidine phosphorylase (TP), Xeloda",
author = "Saif, {Muhammad Wasif} and Glenda Black and Martin Johnson and Suzanne Russo and Diasio, {Robert B}",
year = "2006",
month = "12",
doi = "10.1007/s00280-006-0223-8",
language = "English (US)",
volume = "58",
pages = "771--775",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Radiation recall phenomenon secondary to capecitabine

T2 - Possible role of thymidine phosphorylase

AU - Saif, Muhammad Wasif

AU - Black, Glenda

AU - Johnson, Martin

AU - Russo, Suzanne

AU - Diasio, Robert B

PY - 2006/12

Y1 - 2006/12

N2 - Background: The first reported case of radiation (XRT) recall related to capecitabine described dermatitis in a previously radiated field in a breast cancer patient (Ortman; JCO). We previously reported the first case of recall syndrome manifesting as diffuse gastritis and duodenitis related to capecitabine with prior XRT with 5-FU in a pancreatic cancer patient (Saif; JARCET). We report here another pancreatic cancer patient with a radiation recall receiving capecitabine following capecitabine-XRT. Patients and methods: From April 2004 to June 2005, 20 patients with locally advanced pancreatic adenocarcinoma were treated with capecitabine 1,600 mg/m 2 daily with concomitant radiation (5040cGy) Monday-Friday (weekends off) for a total of 6 weeks, followed by capecitabine 2,000 mg/m 2 daily for 14 days every 3 weeks. One male patient with tumor in the neck and body of pancreas and not infiltrating the duodenum dropped hemoglobin to 7.3 g/dl at the end of the ninth week, and melena on rectal examination. Specimen of primary pancreatic ductal adenocarcinoma was obtained via EUS-guided biopsy before starting XRT on day 1 and utilized for RNA extraction. TP mRNA level was determined by real-time quantitative PCR (RT-Q-PCR). Results: Upper endoscopy revealed gastritis consistent with radiation toxicity. Colonoscopy was negative. Transfusion of three units of packed red blood cells (PRBCs) was given. The dose of capecitabine was reduced by 25%. His anemia continued to progress, a CT scan revealed 39% decrease in the tumor size (PR). Analysis of tumor specimen prior to the start of capecitabine-XRT showed TP expression of 183.16 (high). In addition to TP, DPD was 7.40, and TNF-alpha 4,114.56. Conclusion: We believe this case to be the second case of radiation recall presenting as diffuse gastritis in a patient receiving capecitabine after previous treatment with XRT. Further studies, including the role of TP are warranted into the pathogenesis of this unique phenomenon.

AB - Background: The first reported case of radiation (XRT) recall related to capecitabine described dermatitis in a previously radiated field in a breast cancer patient (Ortman; JCO). We previously reported the first case of recall syndrome manifesting as diffuse gastritis and duodenitis related to capecitabine with prior XRT with 5-FU in a pancreatic cancer patient (Saif; JARCET). We report here another pancreatic cancer patient with a radiation recall receiving capecitabine following capecitabine-XRT. Patients and methods: From April 2004 to June 2005, 20 patients with locally advanced pancreatic adenocarcinoma were treated with capecitabine 1,600 mg/m 2 daily with concomitant radiation (5040cGy) Monday-Friday (weekends off) for a total of 6 weeks, followed by capecitabine 2,000 mg/m 2 daily for 14 days every 3 weeks. One male patient with tumor in the neck and body of pancreas and not infiltrating the duodenum dropped hemoglobin to 7.3 g/dl at the end of the ninth week, and melena on rectal examination. Specimen of primary pancreatic ductal adenocarcinoma was obtained via EUS-guided biopsy before starting XRT on day 1 and utilized for RNA extraction. TP mRNA level was determined by real-time quantitative PCR (RT-Q-PCR). Results: Upper endoscopy revealed gastritis consistent with radiation toxicity. Colonoscopy was negative. Transfusion of three units of packed red blood cells (PRBCs) was given. The dose of capecitabine was reduced by 25%. His anemia continued to progress, a CT scan revealed 39% decrease in the tumor size (PR). Analysis of tumor specimen prior to the start of capecitabine-XRT showed TP expression of 183.16 (high). In addition to TP, DPD was 7.40, and TNF-alpha 4,114.56. Conclusion: We believe this case to be the second case of radiation recall presenting as diffuse gastritis in a patient receiving capecitabine after previous treatment with XRT. Further studies, including the role of TP are warranted into the pathogenesis of this unique phenomenon.

KW - Capecitabine

KW - Dihydropyrimidine dehydrogenase (DPD)

KW - Fluorouracil (5-FU)

KW - Pancreatic cancer

KW - Radiation recall phenomenon

KW - Thymidine phosphorylase (TP)

KW - Xeloda

UR - http://www.scopus.com/inward/record.url?scp=33748476981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748476981&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0223-8

DO - 10.1007/s00280-006-0223-8

M3 - Article

VL - 58

SP - 771

EP - 775

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -